Researchers are hoping to recruit a total of 30,000 people globally, including from 17 sites across the U.K. which include Belfast, Bristol, Cardiff, Dundee, Leicester, London, Manchester, Sheffield and Southampton. It is also the third COVID-19 vaccine to be trialed in the U.K., along with the Oxford vaccine and one from U.S. biotech company Novavax.
Professor Saul Faust, director of the NIHR Southampton Clinical Research Facility and chief investigator for the Janssen phase-three trial, told Sky News: “The Janssen vaccine is very similar to the Oxford/Astra Zeneca vaccine in that it’s an adapted cold virus that can’t replicate in the body and can’t give us a cold and can’t give us coronavirus but it shows the body’s immune system the spike protein to let us make immune responses to it....